Skip to main content
Clinical Trials/ACTRN12615000015549
ACTRN12615000015549
Completed
N/A

What are the effects of a prescribed walking program of 70 minutes per week for 12 weeks versus standard care only for pain, cardiovascular risk, function and quality of life for people with severe knee osteoarthritis and at least moderate risk of cardiovascular disease - a randomised controlled trial.

Jason Wallis0 sites44 target enrollmentJanuary 14, 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Osteoarthritis of the knee
Sponsor
Jason Wallis
Enrollment
44
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 14, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) Adult aged at least 50 years and living independently in the community.
  • (2\) Diagnosed with severe knee osteoarthritis rated as grade III or IV determined radiogaphically.
  • (3\) Have a cardiovascular risk profile with at least 2 total risk factors using stage 2 of the Adult Exercise Screening Tool.
  • (4\) Able to participate safely in the moderate\-intensity physical activity trial using stage 1 of the Adult Exercise Screening Tool.
  • (5\) Able to understand English.

Exclusion Criteria

  • (1\) Live in supported accommodation such as a nursing home.
  • (2\) Report daily resting level of pain to be 9 or 10 on a 0 (no pain) to 10 (worst possible pain) Numerical Pain Rating Scale.
  • (3\) Have very high levels of psychological distress as measured by the Kessler 10 questionnaire with a K10 score \> 29\.
  • (4\) Have an intellectual impairment as measured by the Short Portable Mental Status Questionnaire with a score of 7 or less.
  • (5\) Have a systemic arthritic condition such as rheumatoid arthritis.
  • (6\) Have a neurological condition that affects walking.
  • (7\) Had knee surgery or intra\-articular corticosteroid injection within past six months.
  • (8\) Using oral corticosteroids within four weeks.

Outcomes

Primary Outcomes

Not specified

Similar Trials